November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC
May 1st 2021The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.
Read More
FDA Grants Priority Review to Mobocertinib for EGFR Ex20 Insertion mNSCLC
April 28th 2021The FDA has granted a priority review to mobocertinib as a treatment for adult patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.
Read More
Implementation of Earlier Diagnoses and Testing May Maximize Survival Outcomes for EGFR+ NSCLC
April 9th 2021According to a retrospective analysis presented during the 2021 European Lung Cancer Congress, earlier diagnosis and biomarker testing should be more widely implemented to identify patients with EGFR-positive non–small lung cancer who may benefit for EGFR inhibition.
Read More
Afatinib Shows Encouraging Efficacy and Safety in Late Stage EGFR-Mutant NSCLC
April 8th 2021Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.
Read More
Neratinib Is Effective Against EGFR Exon 18 Mutations in NSCLC
April 6th 2021Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.
Read More
Osimertinib Plus Gefitinib Feasible for First-Line Treatment of EGFR-Mutated
March 9th 2021In an interview with Targeted Oncology, Julia K. Rotow, MD, a medical oncologist at the Dana-Farber Cancer institute, discuses the results of the study of gefitinib in combination with osimertinib as frontline treatment of patients with EGFR-mutated NSCLC.
Read More
Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC
February 24th 2021In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.
Read More
NeoADAURA Trial Launches With Plans to Assess Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC
February 18th 2021n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial
Read More
Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC
January 31st 2021Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.
Read More
DFS Prolonged With Adjuvant Osimertinib Despite Prior Adjuvant Chemo in EGFR+ NSCLC
January 29th 2021In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.
Read More
Amivantamab Achieves Promising Efficacy Outcomes in Previously Treated EGFR Exon 20+ NSCLC
January 29th 2021Treatment with amivantamab induced deep and durable responses as well as promising survival as treatment of patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutation in phase 1 CHRYSALIS trial.
Read More
Osimertinib Plus Savolitnib May Address MET Resistance in EGFR+, MET-Amplified NSCLC
January 28th 2021Patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer and MET resistance treated with osimertinib in combination with savolitinib may be able to overcome resistance, according to final analysis findings.
Read More
Positive Findings From ADAURA Trial Reported, But Questions Remain
December 29th 2020The early unblinding of results from the phase 3 ADAURA clinical trial evaluating osimertinib, a third-generation EGFR tyrosine kinase inhibitor, was met with much fanfare in the oncology community as details of the interim results spread.
Read More
Frontline Regimens Explored for EGFR-Mutated NSCLC
December 20th 2020During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.
Read More
FDA Approves Osimertinib as Adjuvant Therapy for EGFR+ NSCLC
December 18th 2020The FDA has approved osimertinib as an adjuvant therapy for patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, for use following tumor resection.
Read More
New Evidence Supports Targeted Therapies in Early-Stage NSCLC With EGFR Mutations
December 16th 2020During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.
Read More
Trials Demonstrate Which Treatments Physicians Should Use in EGFR+ NSCLC
December 14th 2020Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.
Read More
Phase 3 LAURA Study to Explore Efficacy of Maintenance Osimertinib in Stage III EGFR-Mutant NSCLC
December 14th 2020The phase 3 LAURA clinical trial is currently enrolling patients with stage III, unresectable EGFR-mutant non–small cell lung cancer to explore the efficacy and safety of the third-generation tyrosine kinase inhibitor osimertinib as maintenance therapy following chemoradiation.
Read More
BLA Submitted for Amivantamab as Treatment of Metastatic NSCLC With EGFR Exon 20 Insertion
December 3rd 2020A Biologics License Application was submitted to the FDA seeking approval of amivantamab as treatment of patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on/after platinum-based chemotherapy.
Read More